Inhibiting the Progression of Arterial Calcification with Vitamin K in HemoDialysis Patients (iPACK-HD) Trial: Rationale and Study Design for a Randomized Trial of Vitamin K in Patients with End Stage Kidney Disease by Rachel M Holden et al.
Holden et al. Canadian Journal of Kidney Health and Disease  (2015) 2:17 
DOI 10.1186/s40697-015-0053-xSTUDY PROTOCOL Open AccessInhibiting the progression of arterial calcification
with vitamin K in HemoDialysis patients (iPACK-HD)
trial: rationale and study design for a randomized
trial of vitamin K in patients with end stage kidney
disease
Rachel M Holden1,2*, Sarah L Booth3, Andrew G Day4, Catherine M Clase5, Deborah Zimmerman6, Louise Moist7,
M Kyla Shea3, Kristin M McCabe2, Sophie A Jamal8, Sheldon Tobe9, Jordan Weinstein9, Rao Madhumathi10,
Michael A Adams2 and Daren K Heyland1,4Abstract
Background: Cardiovascular disease, which is due in part to progressive vascular calcification, is the leading cause
of death among patients with end stage kidney disease (ESKD) on dialysis. A role for vitamin K in the prevention of
vascular calcification is plausible based on the presence of vitamin K dependent proteins in vascular tissue, including
matrix gla protein (MGP). Evidence from animal models and observational studies support a role for vitamin K in the
prevention of vascular calcification. A large-scale study is needed to investigate the effect of vitamin K supplementation
on the progression of vascular calcification in patients with ESKD, a group at risk for sub-clinical vitamin K deficiency.
Methods/Design: We plan a prospective, randomized, double-blind, multicenter controlled trial of incident ESKD
patients on hemodialysis in centers within North America. Eligible subjects with a baseline coronary artery calcium
score of greater than or equal to 30 Agatston Units, will be randomly assigned to either the treatment group
(10 mg of phylloquinone three times per week) or to the control group (placebo administration three
times per week). The primary endpoint is the progression of coronary artery calcification defined as a
greater than 15% increase in CAC score over baseline after 12 months.
Discussion: Vitamin K supplementation is a simple, safe and cost-effective nutritional strategy that can easily
be integrated into patient care. If vitamin K reduces the progression of coronary artery calcification it may
lead to decreased morbidity and mortality in men and women with ESKD.
Trial registration: NCT 01528800.
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Contexte: La maladie cardiovasculaire, qui est partiellement attribuable à la calcification vasculaire progressive, est la
cause principale de décès chez les patients atteints d’insuffisance rénale terminale (IRT) en hémodialyse. La vitamine K
pourrait jouer un rôle dans la prévention de la calcification vasculaire, en raison de la présence de protéines dépendantes
à la vitamine K dans les tissus vasculaires, dont l’ostéocalcine. Le modèle animal, de même que des études d’observation,
témoignent du rôle de la vitamine K dans la prévention de la calcification vasculaire. Une étude réalisée à grande échelle
serait nécessaire afin d’étudier l’effet de la supplémentation de vitamine K sur la progression de la calcification vasculaire
chez les patients atteints d’IRT, un groupe à risque pour les carences infracliniques en vitamine K.
Méthode/type d’étude: Nous prévoyons effectuer un essai clinique aléatoire, à double insu et multicentrique auprès de
patients atteints d’IRT, traités en hémodialyse hospitalière en Amérique du Nord. On affectera au hasard les sujets
admissibles qui présentent dans l’artère coronaire un taux de calcium supérieur ou égal à 30 unités d’Agatston, soit au
groupe auquel on administre un traitement (10 mg de phylloquinone trois fois par semaine), soit au groupe témoin
(administration du placebo trois fois par semaine). Le critère d’évaluation principal est la progression de la calcification de
l’artère coronaire, définie comme une augmentation supérieure à 15% (résultat CAC) par rapport au point de référence,
au bout de douze mois.
Discussion: La supplémentation de vitamine K est une stratégie nutritionnelle à la fois simple, sécuritaire et rentable, qui
peut être aisément intégrée aux soins aux patients. S’il s’avère que la vitamine K réduit la progression de la calcification de
l’artère coronaire, il pourrait y avoir une diminution de la morbidité et de la mortalité chez les hommes et les femmes
atteints d’IRT.Background
At least 2 million Canadians have chronic kidney disease
(CKD) and over 20,000 Canadians require life-sustaining
hemodialysis (HD) treatment for end stage kidney disease
(ESKD) [1]. This important health problem carries a high
burden of cardiovascular disease-related mortality. The
elevated risk of cardiovascular disease in men and women
with ESKD is due, in part, to the consequences of vascular
calcification [2]. The Kidney Disease: Improving Global
Outcomes (KDIGO) Clinical Practice Guidelines for
the management of the CKD-mineral bone disorder
recommend screening patients for the presence of
vascular calcification but had no specific recommen-
dations for the treatment or prevention of vascular
calcification [3].
In patients with ESKD, vascular calcification is associated
with abnormalities in divalent ion metabolism (e.g.
phosphate homeostasis) and accompanied by alterations
in bone turnover and increased fracture risk. Vitamin K is
a class of fat-soluble nutrients that function as a co-factor
for the enzyme γ-glutamyl carboxylase (GGCX), which
activates a number of vitamin K-dependent proteins
that are involved in the inhibition of vascular calcification
(e.g. matrix Gla protein (MGP)) and maintenance of bone
health (e.g. osteocalcin). MGP is a local inhibitor of
vascular calcification that is present in the artery media.
MGP requires the vitamin K dependent γ-carboxylation
of its Gla residues in order to acquire calcium binding
activity [4]. Previous studies demonstrate a critical
role of vitamin K in modifying vascular calcification
in animals with CKD [5-9]. Further, patients acrossthe spectrum of CKD have a high prevalence of vitamin K
deficiency and studies consistently indicate that patients
with ESKD are those at greatest risk [7,8,10]. Therefore,
vitamin K may play a key role in the development and
progression of the calcification abnormalities that are
frequently observed in patients with ESKD.
KDIGO research recommendations state that ‘studies
are needed that compare patient outcomes of specified
treatment strategies in response to the presence or absence
of vascular calcification’ [3] and specifically recommends
‘to determine the efficacy of calcification inhibitors in the
prevention or delay of arterial calcification, a prospective,
randomized, placebo-controlled trial evaluating the admin-
istration of vitamin K in CKD stages 4-5D (dialysis) should
be conducted’.
As a result of these recommendations and the potential
role of vitamin K in vascular calcification in ESKD we de-
signed the Inhibit the Progression of Arterial Calcification
with vitamin K in Hemodialysis Patients (iPACK-HD), a
randomized trial designed to determine whether supple-
mentation with phylloquinone (vitamin K1) prevents the
progression of coronary artery calcification in patients
starting hemodialysis. We hypothesize that vitamin K sup-
plementation will inhibit the progression of coronary artery
calcification, measured by coronary artery calcification
(CAC) scores, in patients with ESKD treated with HD.
Methods/Design
Overall study aims
The primary aim of iPACK-HD is to determine if vitamin
K in the form of phylloquinone (10 mg three times per
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calcification, as measured by high resolution computed
tomography over 12 months, compared to placebo. The
secondary aim is to determine if phylloquinone (10 mg
three times per week) decreases the incidence of vertebral
fracture over 12 months, compared to placebo.
Design
The iPACK-HD trial is a randomized, double-blind
(subjects and physicians), placebo-controlled, Phase II,
multicenter study which will be conducted in North
America (Canada and United States). In this study,
incident (within 6 months) hemodialysis patients with
ESKD are randomized to receive 10 mg of phylloquinone
three times per week or matching placebo after each
dialysis session for 12 months.
Ethical considerations
Our study has been (protocol and informed consent)
approved by the Queen’s University and Affiliated
Teaching Hospitals Research Ethics Board (Kingston,
Canada). The study has been approved by Health
Canada. Written informed consent will be obtained
each subject. The trial is registered at clinicaltrials.gov
(NCT01528800).
Inclusion criteria
Participants in the trial must be adult patients (≥18 years
of age) who have ESKD on the basis of irreversible
chronic kidney disease and are new to hemodialysis
treatment (<6 months). Subjects meeting inclusion cri-
teria will be approached by a trained research associate
and, after obtaining informed consent, undergo a high
resolution CT scan to obtain a coronary artery calcium
(CAC) score. Subjects will be eligible for randomization
if they have a CAC score of ≥ 30 Agatston Units (AUs).
Justification for including only those with a CAC score
of ≥ 30 AUs include: 1) 70% of incident HD patients
already have calcification; 2) studies have demonstrated
that HD patients with a CAC score < 30 AU are unlikely
to progress over 12 months [11,12]; 3) patients with high
CAC scores are expected to have a faster rate of progres-
sion allowing us to detect a difference with the intervention
over a shorter period of time [13] and 4) measurement
of CAC scores ≥ 30 AUs have been shown to have high
reproducibility in dialysis patients [14].
Exclusion criteria
We will exclude subjects who: 1) are receiving warfarin;
2) have previous coronary artery bypass grafting or have
coronary stents because of difficulty with CAC score
interpretation; 4) are pregnant, breast feeding, or unwill-
ing to practice abstinence or contraception; 5) have other
severe co-morbid conditions (e.g. malignancy, disablingstroke) and are not expected to survive one year; 6) are
currently enrolled in another interventional trial in which
the treatments or outcomes in that trial would influence
the results of the current study; 7) are unable to provide
signed informed consent.
Random allocation of patients
After obtaining informed consent, the participant will
undergo a CT scan to determine CAC score. If the CAC
score is ≥ 30 AUs, randomization is performed using a
web-based central randomization system at the Clinical
Evaluation Research Unit at Kingston General Hospital.
Randomization is concealed and is stratified by centre
and diabetes mellitus status using permuted blocks of
random size. The prevalence of CAC is significantly
higher in patients with diabetes mellitus therefore it is
critical that the groups be balanced for this risk factor
[15]. A designated research pharmacist(s) will access the
secure web-based centralized randomization system and
obtain the patient’s treatment allocation. The research
pharmacist will prepare the study medication according
to the assigned treatment allocation. The study drug
will be will be dispensed to the HD unit and will be
administrated post-dialysis to the subject. The research
pharmacist will be the only individual who is aware of the
treatment assignment.
Intervention
Patients will receive either 10 mg of phylloquinone or
matching placebo that is identical in sight, taste and
smell, following each dialysis treatment three times/week
for a total of 12 months. Phylloquinone is the only available
form of vitamin K for clinical use in Canada and the
United States. It is currently used for the prevention of
hemorrhagic disease of the newborn, for the reversal of
anticoagulation, and in patients with impaired absorption
of fat-soluble vitamins (e.g. cystic fibrosis). Although
certain forms of vitamin K2 (e.g. menaquinone-4) are
available as health food supplements and/or used clinically
in some countries, phylloquinone is the form most com-
monly consumed in the diet and used clinically in North
America with established efficacy and safety. The single
RCT performed in humans that similarly considered a
CAC score as an endpoint studied phylloquinone [13].
Furthermore, phylloquinone decreased calcification in rats
with experimental CKD. The dose of 10 mg thrice weekly
dose (30 mg/week) was chosen based on the experience of
the Vitamin K Supplementation in Post-menopausal
Women with Osteopenia (ECKO trial) where a similar
weekly dose was administered over 4 years in Canadian
post-menopausal women [16] and also based on pre-
clinical studies demonstrating that a 100-fold increase
in phylloquinone content in rodent chow decreased
the incidence and severity of vascular calcification [9].
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are both well documented in dialysis patients therefore
administration of the 10 mg dose of phylloquinone
will be after each HD treatment to improve adherence. A
placebo control group is justified because phylloquinone
supplementation is not part of standard clinical care, has
not been shown to improve important outcomes and has
not been routinely recommended in the management of
HD patients.
Blinding and protection against bias
At the time of randomization into the study, treatment
assignment is concealed from the local research team,
hemodialysis care team, subjects and families. Subjects
are randomized to receive either phylloquinone or a
matching placebo that is identical in appearance, and
they, their families, their clinical and research teams
will remain blinded to allocation. Recording of baseline
data and relevant clinical follow-up data will be per-




The primary objective of the iPACK-HD trial is to investi-
gate the effect of vitamin K on the progression of coronary
artery calcification in patients with ESKD. The primary
outcome will be the progression of coronary artery
calcium (CAC) score at 12 months as defined by anTable 1 Baseline and ongoing data collection
Baseline data age, sex, ethnicity, height, target weight, waist
circumference
dialysis start date, cause of ESKD
type of dialysis access
medication use
comorbidities
hemoglobin, albumin, Kt/V, urea reduction ratio,
lipid profile
calcium, phosphate, PTH, alkaline phosphatase
vitamin K status (phylloquinone, PIVKA-II,
osteocalcin)
Monthly data Hemoglobin, albumin, Kt/V, urea reduction ratio
Calcium, phosphate
Hospitalizations





PTH, alkaline phosphatase, lipid profile
Q4 monthly
laboratory data
Vitamin K status (phylloquinone, PIVKA-II, osteocalcin)increase of 15% or more from the CAC score measured at
baseline. The coronary calcium scoring protocol is
scanned during a single breath hold with contiguous slice
acquisition at a thickness of 2.5 mm. Imaging is acquired
from the apex of the heart to the inferior margin of the
aortic arch. CAC will be measured using the standard
Agatston/Janowitz protocol in the left main, left anterior
descending artery, circumflex artery and right coronary
artery and composite and the overall CAC score is
calculated using a weighted value assigned to the
highest density of calcification in a given coronary artery.
The scans will be scored by one individual blinded to the
subject and treatment allocation. From the time of
randomization, treatment duration will be 12 months.
Based on the report of Block et al. there is a significant
increase in CAC score at 12 months in patients new to
HD [11]. The median increase in CAC score at 12 months
in patients randomized to a calcium-based phosphate
binder was 142 AU (median % increase of 41%). Two
landmark RCTs conducted in dialysis patients that
evaluated two different regimens (e.g. sevelemer and
cinecalcet compared to calcium and placebo respectively)
demonstrated significant treatment effects on the progres-
sion of CAC at 12 months [17,18]. As such, the 12 month
time frame should be sufficient to demonstrate a treatment
effect of vitamin K should one exist.
A CAC score change (either increase or decrease)
greater than 15% is considered evidence of true change as
opposed to scoring variability [19]. In the Multi-Ethnic
Study of Atherosclerosis, a graded relationship of CAC
progression with coronary heart disease event risk was
demonstrated, with greater CAC progression associated
with greater risk [20]. The authors examined the threshold
at which annualized relative (percent change) progression
was best associated with coronary heart disease events
and a greater than 15% annual increase (HR: 1.4, p < 0.05)
in CAC score was identified. An RCT of an intervention
that differs from iPACK-HD - the use of sevelamer rather
than calcium as a phosphate binder - showed a 30% risk
reduction for CAC progression (defined as an increase
of >15% in CAC score) [11]; participants in this trial were
later shown to have experienced a 60% reduction in
the risk of death [21]. These data support the clinical
relevance of this threshold.
The definitive trial to determine the impact of vitamin
K on cardiovascular disease in this population would
examine calcification-sensitive cardiovascular outcomes.
However, before moving directly to a large scale, very
expensive, Phase III trial powered to examine the
treatment effect on cardiovascular events, we will first
conduct first a Phase II study using CAC scores as a
surrogate outcome. Evidence for an adequate surrogate is
often considered under the framework of the Prentice
criteria. For a given treatment: 1) the treatment affects the
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the surrogate affects the outcome; 4) the effect of the
surrogate on the outcome is independent of the treatment.
For the surrogate outcome of vascular calcification, a sub-
group analysis of an RCT of phylloquinone- the interven-
tion that we propose to study - resulted in significantly
less progression of CAC over 3 years in low-risk elderly
people whose baseline CAC score was ≥ 10 AUs [13]. An
RCT of an intervention that differs from this study - the
use of sevalamer rather than calcium as a phosphate
binder - showed a 30% risk reduction for CAC progression
(increase of >15% in CAC score over 18 months) [11];
participants in this trial were later shown to a 60% reduc-
tion in the risk of death [21]. In an observational study,
CAC progression strongly predicted myocardial infarction
(criterion 3) [22]. If CAC score is not affected by the inter-
vention, we will regard it as unlikely that the intervention
affects patient-important cardiovascular outcomes since
our information about its effects suggest mechanisms that
operate through vascular calcification.
Secondary end pointes
We will evaluate 3 secondary endpoints at 12 months:
(1) the incidence of vertebral fracture will be based on
patient report with adjudicated review of source documen-
tation and anterior and lateral radiographs of the thoracic
and lumbar spine at baseline and at 12 months. Vertebral
fractures will be defined as prevalent and/or incident using
a standard methodology, vertebral morphometry, in
accordance with the recommendations of the National
Osteoporosis Foundation Working Group on Vertebral
Fracture; (2) clinical outcomes including mortality, cardio-
vascular events (acute coronary syndrome, congestive heart
failure, stroke, transient ischemic attack, amputation;
cardiac, cerebral or peripheral revascularization procedure
(bypass, angioplasty, amputation, stents), thrombosis (deep
vein thrombosis, pulmonary embolism, dialysis access
thrombosis (fistula, graft or catheter), causes and lengths of
hospitalization and bone fracture-related events and (3)
changes in biomarkers of vitamin K status: phylloquinone,
and the carboxylation status of the vitamin-K-dependent
proteins (VKDPs) osteocalcin, and prothrombin.
Data collection and follow-up procedures
Patients will be followed from study randomization until
study completion (12 months study period) or patient
censor (see below for details). The study coordinator will
review each patient and their records each month. A
web-based electronic case report form for data entry will
be used. Baseline and ongoing data collection plans are
presented in Table 1.
Co-interventions will be documented each month. It is
not practical to standardize all these treatments and
doing so would limit the generalizability of this study.All study participants will receive a conventional HD pre-
scription (~4 hours thrice weekly, high flux dialysis mem-
brane). Hypertension and dyslipidemia will be managed
according to the participants’ treating physicians. Patients
may receive a general or dialysis-specific (B and C
vitamins) multivitamin preparation. The chronic kidney
disease associated abnormalities in mineral metabolism
(e.g., hyperphosphatemia, hyperparathyroidism) will be
managed by attending nephrologists according to local
clinical practice informed by guidelines [23]. Usual practice
targets and the currently accepted Canadian Society of
Nephrology quality assurance indicators for HD patients
are as follows: calcium (2.2-2.5 mmol/), phosphorus
(<1.8 mmol/L) and PTH (10–50 pmol/L). The majority of
HD patients in Canadian centers receive elemental calcium
as their primary phosphate binder. The American Kidney
Disease Quality Outcomes Initiative (K/DOQI) clinical
practice guidelines recommend targeting a similar phos-
phate level (<1.78 mmol/L) but suggest limiting the total
daily dose of elemental calcium to 1500 mg/day (evidence
level: opinion) [24]. Calcitriol (an active form of vitamin D)
is frequently prescribed, and cinecalcet (a calcimimetic) is
prescribed to a limited extent, for the management of
secondary hyperparathyroidism. Based on current un-
derstanding, phylloquinone treatment would not be
expected to alter levels of calcium or phosphate and
therefore the use of important co-interventions should
not be changed by treatment allocation.
Study censoring
As the primary endpoint requires completion of the CT
scan, follow up for this outcome can only occur if the
patient has survived 12 months. Patients will be censored
and withdrawn from follow-up at the following points in
time: development of an indication for use of warfarin
treatment, kidney transplantation, transfer of patient to
another city which is not a satellite of the original study
centre, and death. With the exception of death, we
will obtain CAC scores at the time of censoring
(within a window of one month before or after the
date of censoring), and use this as a last observation
carried forward, in one of our missing data sensitivity
analyses. Loss to clinical follow up is very unlikely in this
group of patients who are dependent on life-sustaining
therapy. When patients undergo coronary stenting, the
CAC score can no longer be used to assess calcification in
the stented arteries. In these subjects, we will compare
calcification scores from available arteries at follow up
with scores from the same arteries at baseline.
Statistical analysis
Justification of sample size
The primary endpoint is the progression of coronary
artery calcium (CAC) score at 12 months as defined by
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calculations are based on the study of Block et al. In this
study, 109 incident HD patients were randomized to one
of two phosphate binders (calcium versus sevelamer)
and CAC progression (defined as a 15% increase in CAC
score) in patients with a baseline CAC score of ≥ 30 AUs
was determined at 12 months [11]. The proportion of
patients reaching the primary outcome at 12 months
was 86% in patients randomized to calcium and 44% in
patients randomized to sevelamer. The majority of
hemodialysis patients receive calcium as the sole
phosphate binder (82% in Canada) or receive 1500 mg
of calcium daily in combination with another binder.
Therefore, for the purpose of sample size estimation we
conservatively expect the progression rate in our placebo
arm will be lower than the calcium arm of the Block
study (86%). Further, we conservatively estimate that the
addition of phylloquinone will have a more modest
reduction in progression than the calcium-sparing
sevelemer arm of the Block study (44%). Therefore, to
achieve 80% power using a two-sided (alpha = 0.05)
Chi-Squared test to detect a decrease in CAC pro-
gression over 12 months from 70% to 56%, or a relative
risk reduction of 20%, we need to enrol 186 patients
per arm (Power and Sample Size 8, Kaysville, Utah)
(see Table 2). Therefore, we will enroll a total of 448
patients which conservatively accounts for up to 20%
loss to trial completion by 12 months.
Statistical analysis
Analysis of the primary endpoint will be based on the
intention-to-treat principal. The primary analysis is
the between-arm comparison of the proportion of patients
whose CAC score increases by 15% or more from baseline
to 12 months using relative risks and 95% confidence
intervals. This comparison will employ the Mantel-Haenszel
Chi-Squared test stratified by centre and diabetesTable 2 Sample size justification









RRR = Relative risk reduction
Estimate of the power for testing the effect of the intervention. The effect sizes are
over baseline in 12 months. The bolded row indicates estimates utilized for samplemellitus (the pre-stratification factors). The primary
analysis will not adjust for additional covariates, but a
sensitivity analysis will employ logistic regression
stratified for centre and diabetes mellitus and including
any covariates that demonstrate clinically important
imbalance at baseline. A secondary analysis will examine
the change in continuous CAC score adjusting for
baseline CAC score and covariates. In a sensitivity
analysis, the composite outcome of death or progression of
CAC will be examined. In the unexpected event that more
than 20% of patients are lost to follow-up or die we will
employ multiple imputations on the continuous CAC
scores prior to dichotomizing it for analysis. With respect
to the secondary endpoints, we will report the fracture rate,
and the absolute difference in rates, by arm with exact
binomial 95% confidence intervals. Due to the limited
sample size, we will similarly not test for differences
in clinical events however these will be reported by
arm with exact bimodal 95% confidence intervals.
Pilot study
Before advancing to the large-scale trial, a randomized,
double-blind, placebo controlled pilot study of 60 patients
is being carried out to determine the feasibility of a multi-
center RCT. The primary focus of the pilot study is to
evaluate recruitment of trial patients, adherence to proto-
col and completeness of outcome assessment data. After
completion of the pilot trial, we will initiate the definitive
randomized, double-blind, placebo controlled multicenter
trial to evaluate the overall study hypothesis.
Discussion
The presence and extent of vascular calcification as well as
its progression is a significant predictor of cardiovascular
morbidity and mortality in patients with ESKD. Thus,
therapeutic strategies that alter the development or
progression of vascular calcification are likely to be ofPhylloquinone arm
progression rate










described in terms of relative risk reduction for a > 15% increase in CAC score
size calculation for the iPACK-HD trial.
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have focused on treatments that reduce blood levels
of phosphate (e.g. phosphate binders). The change in
CAC score over time has been used as the primary
endpoint in all of these studies [11,17,25-27] and is
the primary endpoint for this proposed trial.
Vitamin K, based on its ability to enhance the function
of MGP as a key vascular calcification inhibitor, is one
potential strategy to reduce the progression of vascu-
lar calcification in patients with ESKD. Vitamin K
exists naturally in two molecular forms - vitamin K1
(phylloquinone) and vitamin K2 (menaquinones) [28].
Phylloquinone is the major dietary form, whereas
menaquinones, with the exception of menaquinone-4,
are believed to be produced by gut bacteria. The extent to
which these manquinones contribute to overall vitamin K
status is unknown. However all forms of vitamin K catalyze
the carboxylation of VKDPs [28,29]. The trials that have
evaluated the impact of vitamin K supplementation
on calcification outcomes have utilized phylloquinone.
Similar results of menaquinone interventions have not
been reported.
MGP is synthesized by VSMCs and requires vitamin K
dependent γ-carboxylation of its specific Glu domains to
actively inhibit calcification [4]. Results of in vitro experi-
ments suggest MGP becomes up-regulated adjacent to
sites of calcification to presumably limit the progression of
vascular calcification in a negative feedback manner [30].
Furthermore, marked MGP up-regulation has been
demonstrated in vivo in aortas of animals with experimen-
tal CKD [31] yet the higher tissue concentrations of MGP
resulted predominantly from accumulation of the uncar-
boxylated form (ucMGP). These data indicate that the
regulation of MGP expression, as well as its activity,
becomes altered in the CKD environment.
Results of preclinical studies demonstrate that a thera-
peutic dose of warfarin depletes tissue vitamin K concen-
trations and markedly increases the susceptibility of all
vessels to vascular calcification in an adenine rat model of
CKD [9]. Furthermore, high dietary phylloquinone signifi-
cantly increases tissue phylloquinone concentrations and
reduces the incidence and severity of vascular calcification
in rats with CKD. These data indicate that, in the setting
of experimental CKD, vitamin K status is important to the
inhibition of vascular calcification. Therefore, factors that
increase vitamin K availability to the vasculature may be
critical to MGP γ-carboxylation and the inhibition of
vascular calcification in patients with CKD.
To date, no trial has examined whether vitamin K
supplementation prevents the progression of coronary
artery calcification in patients with chronic kidney
disease, a group in which high risk has been established.
Studies have consistently demonstrated that vitamin K
deficiency is prevalent in HD and peritoneal dialysispatients, as well as in individuals with earlier stages
of CKD [8-10,32,33]. Furthermore, 82.5% HD patients
have low vitamin K status and this has been attrib-
uted to a lower dietary intake compared to healthy
individuals [34]. While the exact reason for the low
intake is unknown, it may be related to the dietary
regimen prescribed for HD patients. Preliminary stud-
ies in humans have demonstrated that ucMGP levels
augment progressively with CKD stage and are inde-
pendently associated with aortic calcification and
mortality [35]. Taken together, there is considerable
evidence to suggest that patients with kidney failure
are at risk for pathophysiological consequences of
suboptimal vitamin K status.
The studies that have evaluated the impact of vitamin
K supplementation on calcification in patients not at
high risk for vitamin K deficiency and vascular dis-
ease have been positive. In an RCT of healthy adults
60–80 yrs old, supplementation with daily phylloquin-
one (0.5 mg/day) slowed the progression of CAC over
3 years among those with pre-existing CAC at baseline
(AUs > 10) [13]. Similarly, in an earlier RCT, post-
menopausal women who were randomized to receive a
supplement containing 1 mg/day phylloquinone in addition
to minerals and 320 IU vitamin D3 had better carotid
artery distensibility, compliance, and elasticity after
three years, compared to women who received the
mineral supplement alone or the mineral supplement
with vitamin D3 [36].
Clinical trials of vitamin K supplementation to date
have studied individuals who were not at any particu-
lar risk for sub-clinical vitamin K deficiency and had
no history of clinical cardiovascular disease. No trials
have been performed in an at-risk patient group such
as those with kidney disease. There are no national
guidelines that address an optimal intake of vitamin
K outside of HD patients receiving prolonged anti-
biotic therapy. A simple nutrient strategy that modi-
fies arterial calcification could reduce morbidity and
save lives.
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